Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) launches strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225)

Posted on
by

Radiopharmaceutical Stocks
Actinium’s cyclotron produced Actinium-225 material has demonstrated radiochemical and radionuclidic purity identical to current gold-standard methods and has the potential to be significantly lower cost at commercial scale than currently available production methods. Actinium to commit to multi-million-dollar investment and pursue collaborations on a global basis to scale its technology for commercial purposes to support internal programs and address growing demand for Actinium-225

In a groundbreaking announcement from New York on March 11, 2024, Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has unveiled a strategic leap that positions the company at the vanguard of cancer therapy innovation. Known for its pioneering work in Antibody-Radio Conjugates (ARCs) and other targeted radiotherapies, Actinium is now embarking on a trailblazing initiative focused on the manufacture of Actinium-225 (Ac-225), a potent medical isotope with transformative potential in targeted radiotherapy.

Ac-225, an alpha-particle emitter, holds the remarkable capability of killing targeted cancer cells through double-strand breaks in their DNA, a mechanism against which there is currently no known resistance or repair. This feature makes Ac-225 an invaluable asset in the fight against cancer, and Actinium’s strategic move to leverage its proprietary cyclotron-based production method for Ac-225 positions the company as a leader in this critical field.

Innovation at the Core

Actinium’s cyclotron-based method for producing Ac-225 is not only groundbreaking but also steeped in significant intellectual property, with 5 issued U.S. patents and 49 international patents, alongside substantial technical know-how. This method promises to produce Ac-225 that is highly pure and identical to the current gold-standard production method but with potential for lower costs at commercial scale and higher yields. The initiative covers end-to-end solutions, including processing and recycling of Radium-226, and boasts of producing up to 100 mCi of Ac-225 per cycle with over 99% radiochemical purity and 99.8% radioisotopic purity.

Strategic Vision and Global Impact

Sandesh Seth, Actinium’s Chairman and CEO, highlighted the company’s significant investments and efforts in developing this proprietary method and its intellectual property. With the Ac-225 based Actimab-A program advancing to late-stage trials and the increasing development of Ac-225 based programs, Actinium is poised to fully realize the potential of its production method. The initiative is not only a testament to the company’s commitment to innovation but also a strategic move to engage with potential collaborators and partners globally, ensuring supply for its product development efforts and addressing the growing clinical demand for Ac-225.

A Sustainable and Scalable Solution

The relative scarcity of Ac-225 has led to rapidly escalating procurement costs. Actinium’s initiative offers a sustainable and scalable solution to this challenge, with a focus on purifying and recycling from various sources, leveraging existing global cyclotron infrastructure, and developing manufacturing efficiencies. This approach not only addresses the limited availability of source material for Ac-225 production but also positions Actinium as a leader in alpha-particle therapies.

A Visionary Approach to Cancer Treatment

Actinium Pharmaceuticals is not just advancing its proprietary technologies but is also shaping the future of cancer treatment. The company’s efforts in developing targeted radiotherapies aim to significantly improve survival for individuals who have failed existing oncology therapies. With a robust pipeline and a strategic focus on innovation, Actinium is at the forefront of delivering transformative solutions to address the significant and rapidly growing patient population in need of effective cancer therapies.

For traders and investors, Actinium Pharmaceuticals represents a compelling opportunity. The company’s pioneering initiative in the manufacture of Ac-225 not only showcases its leadership in the field of targeted radiotherapy but also underscores its potential for growth and value creation. As Actinium continues to advance its strategic initiatives and engage with global partners, it is poised for significant impact in the oncology space, making ATNM a stock to watch closely in the evolving landscape of cancer treatment.

Other players in the radiopharma market include Lantheus (LNTH), Perspective Therapeutics (CATX), PeptiDream (OTCPK:PPTDF), Telix Pharma (OTCPK:TLPPF), Fusion Pharma (FUSN) and its partner AstraZeneca (NASDAQ:AZN), CASI Pharma (CASI), Radiopharm Theranostics (OTCPK:RDPTF), Cellectar Bio (CLRB), Clovis Oncology (OTCPK:CLVSQ) and QSAM Bio (OTCQB:QSAM).

Source: https://finance.yahoo.com/news/actinium-pharmaceuticals-launches-actinium-225-113000769.html

 

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. InvestorBrandMedia.com has been compensated two hundred and fifty dollars by a 3rd party Bullzeyemedia LLC for content distribution services on ATNM for March 13, 2024. We own zero shares of ATNM. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content.

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: investorbrandmedia@gmail.com
Phone: (954) 593-5597
Country: United States
Website: https://investorbrandmedia.com/